Stem cells: why that market can expand - you discover its sales potential
What are the commercial prospects for stem cells? Visiongain's updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends, technologies, therapies, and opportunities.
That study gives you revenue forecasts to 2023 for the overall world market and its submarkets. See what's happening for those cellular technologies, finding how you can gain.
Read on to explore that industry and see what its future market could be worth.
Forecasts 2013-2023 and other analyses - find the best opportunities
Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you find original analysis. See research and development (R&D) too. You also get 40 tables, 22 charts, and three interviews with organisations in the field.
Now make your search for data on stem cells easier. You can stay ahead in knowledge, then, benefiting your research, analysis, and decisions. Also save time.
Our new study lets you investigate the most promising and lucrative parts of that field - assess technologies and their applications. You hear what's going on and see where the money lies. Try our new report, then, getting feel for the stem cell industry's potential.
The following sections show how you benefit from that investigation.
Prospects from 2013 for the world market and submarkets
What are the secrets of that industry's progress? Along with our prediction of the overall world market for stem cells, our work shows you individual revenue forecasting of five submarkets to 2023 at world level:
- Cancer (oncology)
- Cardiovascular diseases
- Central nervous system (CNS) disorders
- Other therapeutic applications
- Non-therapeutic uses.
There you also explore challenges and strengths of that industry and market, helping you compete and gain advantages. You see prospects for established and emerging technology. That market will grow through the approval and launch of many products.
Our study explains, discussing issues to help your work.
Developments, challenges, and opportunities affecting stem cells
The report lets you assess trends and outlooks for stem cells. There, looking ahead, you find discussions of issues and developments:
- Efforts and outlooks in the US, Japan, Europe, South Korea, China, and Israel
- Regulations and ethics for stem cell research and uses in medicine
- Embryonic stem cells (ESCs) and induced pluripotent adult cells (IPSCs)
- Haematopoietic stem cell transplantation (HSCT)
- Uses for umbilical cord blood and related technologies
- Supply, storage (banking) and processing of the cellular material.
- Activities of Osiris Therapeutics, Gamida Cell, Novartis, Baxter, NeoStem, and others
- Approvals of therapies and other products to expand and progress the sector
- Orphan diseases and other under-treated conditions
- Metabolic applications - diabetes and liver treatments
- Agents for osteogenesis and treating autoimmune disorders
- Cell-based assays - uses in diagnostic tests and devices.
For example, the author of the report said: "Companies are targeting ischaemic disorders of the cardiovascular and cerebrovascular systems, in 2012 the biggest causes of death worldwide. More than 20 stem cell products tackling those diseases are in clinical trials."
Discover, then, what the present and future hold.
Stem cells - what 2017 market value?
What happens next? From 2013, stem cell products and services hold great potential for investments, technological advances and sales. Our new report predicts the world market for those technologies will reach $10.7bn in 2017, achieving high growth from 2013 to 2023.
Prospects for those medical tools and systems are strong, and from 2013 to 2023 there will arise many opportunities. Our analyses show you the possibilities, helping you stay ahead.
Information found nowhere else
In particular, then, our new study gives you these advantages:
- Revenues to 2023 for stem cells at world level, with forecasting of five submarkets - assess prospects for investments and sales
- Interviews with other authorities - discover what participants from industry and academia think, say, and do, helping you stay ahead
- Prospects for established competitors and new entrants - explore activities, results, R&D, and outlooks for future success.
With that report you are less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Explore progress and possibilities. Also find how you can save time and get recognition for insight.
Stem cells - assess commercial potentials now, seeing what you can gain
Our new report is for everyone analysing biotechnology for healthcare - pharmaceuticals, diagnostics, and medical devices. There you find sales predications with discussions. Avoid missing out - please order the report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. OVERVIEW OF THE STEM CELLS MARKET, 2013-2023
2.1 Strong Market Performance Expected 2013-2023
2.2 Cancer Segment Represents Bulk of Stem Cell Therapy Revenues, 2013
2.2.1 Other Therapeutic Areas to Gain Ground by 2023
2.2.2 Market Breakdown Focuses on Key Therapeutic Areas
2.3 Which Types of Stem Cells Matter for the Market?
2.3.1 The Discovery of Stem Cells
2.3.2 Embryonic Stem Cells (ESCs) Enter the Picture
2.3.3 Only ESCs and Induced Pluripotent Adult Cells (IPSCs) Have Pluripotency
2.3.4 MSCs Prominent in Clinical Trials
2.3.5 Autologous and Allogeneic Properties
2.3.6 Different Cell Advantages and Disadvantages
2.4 The Global Regulatory Environment for Stem Cells
2.4.1 US: No Morality Clause, Much Venture Capital
18.104.22.168 ESC Controversy Now Settled?
22.214.171.124 FDA Vs Regenerative Sciences
2.4.2 Japan: Liberal on hESCs
126.96.36.199 First-in-Human iPSC Trial Announced in 2013
2.4.3 Europe: No Consistent Position Across the Continent
188.8.131.52 The BrГјstle Ruling: Dead and Buried?
184.108.40.206 The UK Leads in European Stem Cells R&D
2.4.4 Rest of the World
220.127.116.11 South Korea: Leading the Way in MSC Approvals
18.104.22.168 China: Liberal Laws on Stem Cell Research
22.214.171.124 Israel - Long-Term Research Activity
126.96.36.199 'Stem Cell Tourism'
3. STEM CELL CANCER THERAPEUTICS SEGMENT 2013-2023
3.1 HSCT Will Underpin the Growth of the Cancer Segment in the 2013-2023 Period
3.2 Stem Cells: 45 Years as a Major Part of Blood Cancer Treatment
3.2.1 Autologous HSCT Operations Still Dominate Segment
3.2.2 Allogeneic HSCT: More Rejections, Fewer Relapses
3.2.3 GvHD: The Major Issue for HSCT
3.2.4 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
3.2.5 The Rise of Umbilical Cord Blood
3.2.6 Around 60,000 HSCT Operations Performed Worldwide in 2012
3.2.7 HSCT Costly, Medicare Coverage Selective
3.2.8 Haematological Malignancies the Major Indication for HSCT
3.2.9 HSCT Addresses Cancers Representing a $20bn+ Market
3.2.10 From Successful Procedure to Successful Products? The Next Stage for the HSCT Sector
3.3 Pipeline Maturing, with First Approval in 2012
3.3.1 Osiris Therapeutics - Prochymal Finally Makes it to Market
188.8.131.52 Osiris Leads the Pack in Stem Cell Therapeutics
184.108.40.206 Using MSCs for Immunosuppression
220.127.116.11 Positive Results in Acute Paediatric GvHD
18.104.22.168 An Important Role to Play in the Future of HSCT
3.3.2 The Clinical-Stage Pipeline: Two More Candidates in Phase 3
3.3.3 Gamida Cell - StemEx: The Next Stem Cell Product to Market?
22.214.171.124 Survival at 100 Days Improved by StemEx in Latest Trial
126.96.36.199 FDA Remains Unconvinced
188.8.131.52 NiCord Heads Up a Pipeline of New Cell Therapy Products
184.108.40.206 NiCord Promising So Far
3.3.4 Mesoblast - Using Mesenchymal Precursors to Enrich Cord Blood
220.127.116.11 Phase 3 Trial Measuring 100-Day Survival Rates and Engraftment Efficiency
18.104.22.168 A Competitor for Gamida Cell?
3.3.5 Novartis Pharmaceuticals - Cord Blood Transplant Candidate
22.214.171.124 Swiss Giant with Multiple Stem Cell Interests
3.3.6 Medipost - Promostem Uses Cord Blood MSCs to Prevent GvHD
3.3.7 CytoMedix - Improving Engraftment
3.3.8 Lentigen - LG631-CD34 for Chemoprotection
3.3.9 Athersys - MultiStem Trialled in Blood Cancers
3.3.10 HomeoTherapy - MSCs for GvHD
3.3.11 Pluristem Soon to Join the Hunt?
3.3.12 Other Stem Cell Oncology Prospects
3.3.13 Ancillary Products for the HSCT Setting
3.3.14 Targeting Cancer Stem Cells (CSCs)
3.3.15 Immunovative Therapies - Building on HSCT for a Cellular Anticancer Therapy
3.4 How Much Growth Potential Do Stem Cells Have in Cancer Indications?
4. STEM CELL CARDIOVASCULAR THERAPEUTICS SEGMENT, 2013-2023
4.1 Segment Set for 40%+ CAGR in 2013-2023 Period
4.2 Can Stem Cells Heal the Heart and Vasculature?
4.2.1 AMI, CLI and Stroke Major Ischaemic Disease Targets
4.2.2 Cerebrovascular Treatments for Stroke
4.2.3 What is the Heart's Own Stem Cell?
4.2.4 MSCs Support Cardiac Stromal Lineages
4.2.5 The Mysterious Efficacy of Adult Stem Cells in the Heart
4.2.6 Cells Have Therapeutic Effects Despite Rapid Clearance
4.2.7 A New Generation of Cardiovascular Stem Cells May Need to Look Beyond MSCs
4.2.8 Are MSCs Safe and Efficacious?
4.2.9 Cardiovascular and Cerebrovascular Conditions Are World's Most Fatal Diseases
4.2.10 Cardiovascular Drugs Market Exceeded $110bn in 2012
4.3 Cardiovascular Stem Cell Pipeline and Products, 2013-2023
4.3.1 FCB-Pharmicell - Hearticellgram-AMI, the First Approved Cardiovascular Stem Cell Treatment
126.96.36.199 Performance So Far
188.8.131.52 Will Hearticellgram Impress Regulators Outside Korea?
4.3.2 The Largest Pipeline in the Stem Cells Market
4.3.3 Baxter: Big Pharma Leader in Cardiovascular Stem Cells
184.108.40.206 Exercise Tolerance and Angina Frequency Reduced
220.127.116.11 Wider Potential for this Treatment
4.3.4 Cardio3 Bioscience - Cardiopoiesis Platform for Heart Regeneration
18.104.22.168 Positive Phase 2 Data
22.214.171.124 Phase 3 Trial Begins Amid Controversy
4.3.5 Bioheart - MyoCell in new MIRROR Trial
126.96.36.199 Muscle Cells the Basis of MyoCell
188.8.131.52 Seeking Expanded Access for Compassionate Use
4.3.6 NeoStem - Diversified Outfit with One of the Leading Candidates
184.108.40.206 AMR-001 to Treat Acute Myocardial Infarction
220.127.116.11 NeoStem Head-to-Head with Baxter in the HSC Cardiovascular Treatment Space
4.3.7 Aastrom Biosciences: Ixmyelocel-T for Cardiovascular Disease
18.104.22.168 A Complex Multicellular Mixture
22.214.171.124 Company Now Focusing on DCM
4.3.8 Athersys - MultiStem is a Potential Cardiovascular Treatment
126.96.36.199 Addressing Ischaemic Stroke
4.3.9 CytoMedix - Three Clinical Candidates in the Cardiovascular Segment
188.8.131.52 ALD-401 - Repairing Stroke Damage?
184.108.40.206 ALD-301 - Entering Phase 2 in PAD Patients
220.127.116.11 ALD-201 - Signs of Efficacy in Phase 1 Heart Failure Trial
4.3.10 TCA Cellular Therapy - Mesendo Autologous Treatments
18.104.22.168 Preparing for Phase 3 with CLI Treatment
4.3.11 Medistem - The 'Universal Donor' Cell
22.214.171.124 Trial in CLI the First Clinical Test for ERC
126.96.36.199 Scalability a Major Advantage for Medistem
4.3.12 Stemedica Cell Technologies - Ischaemic Tolerant Stem Cell Platform
188.8.131.52 Two Trials in Progress for Allogeneic MSCs
4.3.13 Mesoblast - Cell Therapy for Myocardial Infarction
184.108.40.206 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
4.3.14 Pluristem - Cell Therapy for Myocardial Infarction
220.127.116.11 Progress in PAD and CLI
4.3.15 Osiris - Prochymal Cell Therapy for Myocardial Infarction
4.3.16 Cytori Therapeutics - Adipose-Derived Cells for Acute Myocardial Infarction
4.3.17 Stempeutics - Emerging Bangalore Company Targets CLI
4.3.18 BioCardia - Comparing Autologous and Allogeneic MSCT Options
4.3.19 Apceth - Mesenchymal Stem Cells for Advanced Peripheral Arterial Occlusive Disease
4.3.20 Arteriocyte - Nanex Technology to Treat CLI
4.3.21 Capricor - Using Cardiosphere-Derived Cells for Heart Repair
18.104.22.168 Phase 1/2 Trial Now Underway
4.3.22 Garnet BioTherapeutics - GBT009 for Cardiac Tissue Preservation
4.3.23 Biogenea-Cellgenea - Cardiogenea to Enter the Clinical Pipeline
4.3.24 Other Stem Cell Cardiovascular Prospects
4.4 Can Stem Cells Be a Game-Changer in the Cardiovascular Sphere?
5. STEM CELL CNS THERAPEUTICS SEGMENT, 2013-2023
5.1 The Biggest Stem Cell Therapeutic Revolution of All will Begin to Take Shape by 2023
5.2 Stem Cells the Best Hope for Many Serious CNS Conditions
5.2.1 Segment Awaits First Breakthrough Approval
5.2.2 Human NSCs Successfully Isolated
5.2.3 NSCs Reach the Clinic
5.2.4 CNS Segment the Major Focus for ESC Research
5.2.5 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
5.2.6 Could 'Resetting' the Immune System Treat MS?
5.2.7 ALS: Rare Disease Could be the First Neurodegenerative Condition to Fall to Stem Cell Treatment
5.2.8 PD: Positive Signs from Early Experiments in Cellular Treatment
5.2.9 Dry AMD: A Major Global Unmet Need
5.2.10 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
5.3 Which Product Will Be First to Phase 3 Trials in the CNS?
5.3.1 BrainStorm Cell Therapeutics - NurOwn Cells for Spinal Cord Injury and ALS
22.214.171.124 Validating the NurOwn Approach
126.96.36.199 ALS Trial Ongoing
5.3.2 Neuralstem - Neural Stem Cells for Synaptic Repair and Neuroprotection
188.8.131.52 Phase 2 Trial in ALS Enrolling by Invitation
184.108.40.206 Chronic Spinal Cord Injury Treatment to Follow
5.3.3 Mesoblast - A New Option in Neovascular AMD?
220.127.116.11 CNS Stem Cells from Dental Pulp
5.3.4 Advanced Cell Technology - Leading the Field in ESC Clinical Trials
18.104.22.168 Continued Progress in Stargardt's Macular Dystrophy in 2013
22.214.171.124 Early Signals of Efficacy?
5.3.5 StemCells - The Leading Player in the NSC Space?
126.96.36.199 HuCNS-SC Product Proving Itself in Rare Indications
188.8.131.52 Moving on to Spinal Cord Injury and AMD
184.108.40.206 Alzheimer's Disease and Stroke to Follow?
5.3.6 TCA Cellular Therapy - Mesendo for ALS
5.3.7 Corestem - Autologous Bone Marrow Stem Cells for ALS
5.3.8 ReNeuron - ReN001 is a Potential New Stroke Treatment
220.127.116.11 Foetally-Sourced Cells Have Wide Potential Application
5.3.9 SanBio - SB623 for Ischaemic Stroke
18.104.22.168 Future SanBio Programmes at Preclinical Stage in 2013
5.3.10 Pfizer - Collaborating on the London Project to Cure Blindness
5.3.11 Stemedica Cell Technologies- Ischaemic RPE Cells
22.214.171.124 NSC Lines from Donated Brain Tissue
5.3.12 NeuroGeneration - Investigating Human NSCs
5.3.13 Companies at Preclinical Stage
126.96.36.199 RhinoCyte - Stem Cells from the Nasal Passage to the Spinal Cord
188.8.131.52 Theradigm - Neural Cells for CNS Disorders
184.108.40.206 Biotime - Targeting AMD with ESCs
5.3.14 Other Companies with Technologies of Interest
220.127.116.11 iPierian - Bringing iPSCs to the CNS Market?
5.4 Will CNS Stem Cells Fulfil Their Perceived Therapeutic Potential?
6. STEM CELL THERAPEUTICS IN OTHER DISEASE AREAS, 2013-2023
6.1 A Diverse Range of Approvals will Drive Segment Growth to 2023
6.2 Other Indications for Stem Cell Treatment
6.2.1 Curing Orphan Diseases with HSCT
6.2.2 Genetically-Modified HSCs May Cure HIV, Among Other Diseases
6.2.3 Stem Cells for Osteogenesis
6.2.4 Several Stem Cell Osteobiologics Already Marketed
6.2.5 Perianal Fistula Treatment Indicates Stem Cells' Potential in Tissue Repair
6.2.6 A New Option for Many Autoimmune Disorders
6.2.7 Can Stem Cells Cure Diabetes?
6.2.8 Mending the Liver
6.2.9 Long-Range Possibilities
6.3 Which Other Indications Will See the First Approvals?
6.3.1 Medipost - Cartistem, 'World's First Allogeneic Stem Cell Drug'
6.3.2 Anterogen - Cupistem, Adipose-Derived Stem Cells for Anal Fistula
6.3.3 R&D Ranges Broadly Across Disease Areas
6.3.4 TiGenix - Phase 3 Data for Cx601 Expected In July 2014
18.104.22.168 'First Ever Signal of Clinical Activity of a Cell Therapy in RA'
22.214.171.124 ChondroCelect Already on the Market
6.3.5 Osiris Take on Crohn's Disease - Another Possible Use for Prochymal
126.96.36.199 Chondrogen: New Osteoarthritis Candidate
6.3.6 Mesoblast - Treating Back Pain and Disc Degeneration
188.8.131.52 IV Precursor Cells Seeking Out New Indications
6.3.7 Athersys - Pfizer Collaboration in Ulcerative Colitis
6.3.8 Celgene Cellular Therapeutics - Targeting Multiple Inflammatory Conditions
6.3.9 AlloCure - AC607 for Anti-Inflammatory Effects
6.3.10 Gamida Cell - Potential Sickle Cell Anaemia Treatment Option
6.3.11 GlaxoSmithKline - GSK2696273 Stem Cell Gene Therapy
6.3.12 Alliancells Bioscience Corporation - Possible RA Treatment
6.3.13 ViroMed - Stem Cell Gene Therapy for Chronic Granulomatous Disease
6.3.14 S-Evans Biosciences - Menstrual Stem Cells for Hepatic Disease
6.3.15 Cytomedix - ALD-601 for Lysosomal Storage Diseases
6.3.16 Cellonis Biotechnology - Commercialising Research on Stem Cells in Diabetes
6.3.17 Other Companies in the Hunt for New Stem Cell Applications
6.4 Can We Expect A Clinical Breakthrough for Stem Cells in Other Therapeutic Areas by 2023?
7. NON-THERAPEUTIC APPLICATIONS OF STEM CELL TECHNOLOGIES SEGMENT, 2013-2023
7.1 Cell-Based Assays will Help Expand this Segment in 2013-2023 Period
7.2 A Diverse Range of Business Models Emerging
7.2.1 Stem Cell Banking: Growing Demand Worldwide
7.2.2 Stem Cell Supply and Processing: iPSCs the New Driver?
7.2.3 Stem Cell-Based Assays: Major Potential for Preclinical Screens
7.2.4 Research, Reagents, and Other Non-Therapeutic Stem Cell Revenue Streams
7.3 What Will the Main Growth Areas be for Non-Therapeutic Stem Cell Activities?
8. QUALITATIVE INDUSTRY ANALYSIS, 2013
8.1 Strengths: Stem Cells Are Finally Proving Their Worth
8.2 Weaknesses: Many Difficulties Still to Overcome
8.3 Opportunities: Stem Cells Have Unprecedented Clinical Potential
8.4 Threats: Regulatory and Commercial Instability Threatens the Field
8.5 Social Concerns: A Controversial Technology
8.6 Technological Developments: Stem Cell Science Still on the March
8.7 Economic Factors: Funding Gaps a Concern
8.8 Political Issues: State Attitudes Key to Research Environment
9. RESEARCH INTERVIEWS
9.1 Interview with Dr Antonio Lee, Associate Director Business Development, Medipost
9.1.1 Overview of Cartistem
9.1.2 Global Regulatory Variation in Cellular Cartilage Repair Field
9.1.3 Precedents and Competition for Cartistem
9.1.4 Cord Blood-Derived MSCs: Advantages and Challenges
9.1.5 Medipost's Pipeline
9.2 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
9.2.1 Improved Funding in the Stem Cells Field
9.2.2 MSCs: Major Potential or Merely a Placeholder?
9.2.3 CIRM Investment Strategies
9.2.4 The Changing Regulatory Environment Worldwide
9.2.5 Key Trends for the Next Five to Ten Years
9.3 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
9.3.1 Overview of the Current State of the iPSC Field
9.3.2 Genomic Stability and Other Potential Issues for iPSCs
9.3.3 Potential for Treating and Modelling Diseases with iPSCs
9.3.4 Reprogramming Without Transgenes
9.3.5 Possibilities for Directly-Converted Cells
10.1 Stem Cell Technologies Will Begin to Break Through by 2017
10.2 Market to Record Double-Digit CAGR to 2023
10.3 Oncology and Non-Therapeutic Uses to Dominate To 2017
10.4 CNS and Cardiovascular Treatments to Gain Market Share by 2023
10.5 Strong R&D Pipeline to Drive Market Growth
10.6 Radical Clinical and Commercial Possibilities for Stem Cells in the Longer Term
10.7 Challenges for the Stem Cells Market
10.8 Concluding Remarks
LIST OF FIGURES
Figure 2.1 Stem Cells Market: Revenues ($m), 2012-2023
Figure 2.2 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Figure 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Figure 2.4 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Figure 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012-2023
Figure 2.6 Stem Cells Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023
Figure 2.7 The Early History of Stem Cell Discovery and Development
Figure 3.1 Cancer Segment: Revenues ($m), 2012-2023
Figure 3.2 Drivers and Restraints for Stem Cell Cancer Therapies, 2013
Figure 4.1 Cardiovascular Segment: Revenues ($m), 2012-2023
Figure 4.2 Drivers and Restraints for Stem Cell Cardiovascular Therapies, 2013
Figure 5.1 CNS Segment: Revenues ($m), 2012-2023
Figure 5.2 Drivers and Restraints for CNS Stem Cell Therapeutics, 2013
Figure 6.1 Other Therapeutic Areas Segment: Revenues ($m), 2012-2023
Figure 6.2 Drivers and Restraints for Stem Cell Therapeutics in Other Therapeutic Areas, 2013
Figure 7.1 Non-Therapeutic Applications Segment: Revenues ($m), 2012-2023
Figure 7.2 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities, Revenues ($m), Segment Share (%), 2012
Figure 7.3 Drivers and Restraints for Non-Therapeutic Applications of Stem Cells, 2013
Figure 10.1 Stem Cell Technologies Market Revenues ($m), 2012-2017
Figure 10.2 Stem Cell Technologies Market Revenues ($m), 2018-2023
Figure 10.3 Stem Cell Market Segments: Revenues ($m), 2012-2017
Figure 10.4 Stem Cell Market Segments: Revenues ($m), 2018-2023
Advanced Cell Technology
Alliancells Bioscience Corporation
Aristotle University of Thessaloniki
Beth Israel Deaconess Medical Center
BrainStorm Cell Therapeutics
California Institute for Regenerative Medicine (CIRM)
California Stem Cells
Cedars-Sinai Heart Institute
Celgene Cellular Therapeutics
Cell Cure Neurosciences
Cellular Dynamics International
Cha General Hospital
China Cord Blood Corporation
Clal Biotechnology Industries
Cord Blood America
ES Cell International
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Hadassah Medical Organization
Harvard Stem Cell Institute
Human Fertilisation and Embryology Authority (HFEA)
Human Stem Cell Institute
Institute of Biomedical Research (Japan)
International Stemcell Services
iPS Academia Japan
Israel Healthcare Venture
Israel Stem Cell Society
Johnson & Johnson
Medical Research Council (UK)
Merck & Co.
MetaCyte Business Lab
Ministry of Food and Drug Safety, Korea
National Marrow Donor Program (US)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Progenitor Cell Therapy
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Saneron CCEL Therapeutics
Seoul National University
South Korea Food and Drug Administration (KFDA)
Stem Cell Authority
Stem Cell Sciences
Stem Cell Therapeutics
Stemedica Cell Technologies
Stemina Biomarker Discovery
TCA Cellular Therapy
Teva Pharmaceutical Industries
United States District Court for the District of Columbia
University College London
University of California, San Diego
University of Heidelberg
University of Kyoto
University of Minnesota
University of Texas Health Science Center
University of Wisconsin Alumni Research Foundation
World Health Organization (WHO)
Indications for Stem Cell Treatment
This segment includes all areas of therapeutic stem cell R&D outside the treatment of cancers, the heart and vasculature, and the CNS and eyes. This leaves a large range of disease targets. Some are more plausible than others, and only three are addressed by formally-approved stem cell therapies: various non-cancerous blood disorders treated by HSCT; osteobiologics; and tissue damage as a complication of Crohn’s disease. However, the potential for stem cells extends into many other indications.
Curing Orphan Diseases with HSCT
The indications for HSCT outside oncology are broad and varied; for the most part, these are orphan diseases with small patient populations.
In rare cases, HSCT can cure these diseases: for example, HSCs from HLA-matched sibling donors can cure sickle cell disease, and, more problematically, beta-thalassemia.
Genetically-Modified HSCs May Cure HIV, Among Other Diseases
One likely future extension of this principle will be autologous stem cell gene therapy: autologous HSCs will be modified to correct a genetic condition, then reimplanted. Studies have shown that Wiskott-Aldrich syndrome (an immunodeficiency disorder) can be cured by autologous HSCT if the HSCs are first virally modified to express the correct gene. Bluebird Bio has two clinical-stage programmes of this sort, addressing adrenoleukodystrophy and beta-thalassemia (they are not covered here since this is primarily a gene therapy platform; however, the distinction is somewhat subjective).
The material was prepared in October, 2013.
Table 2.1 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 2.2 Stem Cells Market: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 2.3 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012
Table 2.4 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017
Table 2.5 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017
Table 2.6 Stem Cells Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023
Table 2.7 Stem Cells Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023
Table 2.8 Potency and Source of Stem Cells
Table 2.9 Germ Layers and Their Associated Types of Cells and Organs
Table 2.10 Main Types of Stem Cells and Their Properties, 2013
Table 2.11 Sources of Stem Cells for Medical Applications, 2013
Table 3.1 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 3.2 Cancer Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 3.3 Comparative Characteristics of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2013
Table 3.4 Indications with Medicare Coverage for HSCT, 2013
Table 3.5 Malignancies and Other Haematological Diseases Treated with HSCT, 2013
Table 3.6 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 4.1 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 4.2 Cardiovascular Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 4.3 Selected Companies Developing Stem Cell Cardiovascular Treatments, 2013
Table 5.1 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 5.2 CNS Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 5.3 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 6.1 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 6.2 Other Therapeutic Areas Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 6.3 Diseases Other than Cancers to be Treated with HSCT, 2013
Table 6.4 Processes Involved in Bone Healing
Table 6.5 Selected Companies Developing Stem Cell Cancer Treatments, 2013
Table 7.1 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017
Table 7.2 Non-Therapeutic Applications Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023
Table 7.3 Non-Therapeutic Applications of Stem Cells: Estimated Breakdown of Activities, Revenues ($m), Segment Share (%), 2012
Table 7.4 Selected US Stem Cell Banking Companies, 2013
Table 7.5 Selected Non-US Stem Cell Banking Companies, 2013
Table 7.6 Selected Stem Cell Supply and Processing Companies, 2013
Table 7.7 Selected Companies with Involvement in Stem Cell-Based Assays, 2013
Table 7.8 Selected Companies with Other Stem Cell-Related Activities, 2013
Table 8.1 World Stem Cells Market: Strengths and Weaknesses, 2013
Table 8.2 World Stem Cells Market: Opportunities and Threats, 2013
Table 8.3 World Stem Cells Market: STEP Analysis, 2013-2023
Table 10.1 Stem Cell Products: Approved and in Late-Stage Trials, 2013